Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01835041 · ClinicalTrials.gov registry record · Phase 1
CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer
A Phase 1 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT01835041 is a Phase 1 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 21 participants.
The verdict
NCT01835041, a Phase 1 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of CPI-613 when given together with combination chemotherapy in treating patients with metastatic pancreatic cancer. Drugs used in chemotherapy, CPI-613, leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Interventions
- DRUG oxaliplatin
- DRUG fluorouracil
- DRUG leucovorin calcium
- DRUG irinotecan hydrochloride
- DRUG 6,8-bis(benzylthio)octanoic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2013-04 |
| Est. Completion | 2023-03-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01835041
The ClinicalTrials.gov registry entry for NCT01835041 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which oxaliplatin is the first listed.
NCT01835041 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01835041 about?
NCT01835041 is a clinical study titled "CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer". This phase I trial studies the side effects and best dose of CPI-613 when given together with combination chemotherapy in treating patients with metastatic pancreatic cancer. Drugs used in chemotherapy, CPI-613, leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin, work in dif...
What is the current status of trial NCT01835041?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2013-04. Estimated completion is 2023-03-16.
What interventions are being tested in trial NCT01835041?
The interventions under investigation include: oxaliplatin (DRUG), fluorouracil (DRUG), leucovorin calcium (DRUG), irinotecan hydrochloride (DRUG), 6,8-bis(benzylthio)octanoic acid (DRUG).
Who is sponsoring clinical trial NCT01835041?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.